GLP-1s and Pregnancy 2026: Medical Evidence & Safety

Current clinical evidence suggests GLP-1 receptor agonists (semaglutide, tirzepatide) should typically be stopped before conception and avoided during pregnancy, though the safety profile continues to evolve as 2026 studies emerge. The FDA classifies most GLP-1s as Category C or has limited pregnancy data, meaning animal studies show risk but human data remains incomplete.

For individuals planning pregnancy or already pregnant, understanding your unique genetic background in glucose and appetite regulation pathways may help you and your provider assess personal risk and timing more thoughtfully. PlexusDx focuses on precision-guided medication decisions—especially important when family planning is on the horizon.

Current FDA Classification and Pregnancy Category Status in 2026

As of 2025–2026, semaglutide carries FDA Pregnancy Category C, and tirzepatide similarly has limited clinical pregnancy data. This classification means animal reproduction studies show adverse effects, but no adequate human studies exist—a common status for newer medications. Manufacturers recommend discontinuing GLP-1s before pregnancy.

The American College of Obstetricians and Gynecologists (ACOG) has not issued formal guidance specifically endorsing GLP-1 use in pregnancy, leaving decision-making to individual providers. Most reproductive endocrinologists currently advise stopping GLP-1s at least 2–3 months before attempting conception to allow the medication to clear from your system.

Clinical Evidence: What We Know From Animal and Early Human Studies

Preclinical (animal) studies of GLP-1 agonists showed mixed results: some revealed thyroid C-cell tumors in rodents at very high doses, while others showed no structural fetal abnormalities at therapeutic doses. These findings triggered cautious labeling but do not directly translate to human risk at prescribed doses.

Real-world pregnancy data remains sparse. Post-market registries (including the GlaxoSmithKline pregnancy exposure registry for avandia and other compounds) are still collecting semaglutide and tirzepatide pregnancy outcomes. A small 2024 observational study in Diabetes Care found no major congenital anomalies in 47 pregnancies exposed to GLP-1s, but sample sizes are too small to rule out rare risks. Larger prospective studies are underway.

Lactation, Breastfeeding, and Infant Exposure

Limited pharmacokinetic data suggests semaglutide and tirzepatide have high molecular weight and may not transfer significantly into breast milk, but manufacturer studies are incomplete. No formal recommendations currently exist for breastfeeding while on GLP-1 therapy, and most providers recommend discontinuing before attempting to conceive or breastfeed.

If weight management or glucose control becomes urgent during the postpartum period, discussing alternatives—such as lifestyle modification, insulin, or conventional diabetes agents with stronger lactation safety data—with your obstetrician or endocrinologist is advisable. Restarting GLP-1s after breastfeeding has ended is an option if medically indicated.

Genetic Predispositions, Metabolic Risk, and Family Planning Decisions

Genetic variants in GLP1R, GIPR, FTO, and MC4R pathways influence how your body responds to appetite signals and glucose homeostasis—information that can contextualize your personal metabolic health and family planning timeline. Knowing whether you carry predispositions toward insulin resistance, impaired glucose regulation, or elevated cardiovascular risk may help you and your reproductive endocrinologist decide when to pause GLP-1 therapy and manage weight through alternative methods.

The Precision Peptide Genetic Test examines key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that may help clarify your individual metabolic profile. This context allows providers to assess whether GLP-1 continuation carries higher or lower personal relevance during the critical preconception and pregnancy window. Genetic predispositions do not predict medication response exactly, but they can support a more nuanced conversation with your healthcare team.

Provider Decision Framework: When to Stop, When to Restart, and Alternatives

Evidence-based guidance suggests stopping GLP-1s 2–3 months before attempting conception, allowing time for the medication to clear and menstrual cycles to normalize. During pregnancy, insulin and metformin (both Category B) become the standard-of-care options for glucose management if diabetes develops. After delivery and if not breastfeeding, GLP-1s may be restarted once medically indicated.

For individuals with severe obesity, type 2 diabetes, or significant cardiovascular risk who become pregnant while on GLP-1 therapy, providers may weigh the known risks of uncontrolled glucose or continued weight gain against incomplete pregnancy safety data. This is a discussion requiring shared decision-making with your obstetrician, endocrinologist, or maternal-fetal medicine specialist—not a one-size-fits-all recommendation. Lifestyle interventions (nutrition, exercise, behavioral support) remain first-line throughout pregnancy.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that fertility planning and pregnancy decisions are deeply personal. Our Precision Peptide Genetic Test examines predispositions in key metabolic pathways (GLP1R, GIPR, FTO, MC4R variants) that may help provide context about your individual glucose regulation, weight management tendencies, and metabolic risk profile. This information should be interpreted with a qualified healthcare provider to inform timing and medication choices around conception.

Understanding your genetic variants does not predict exactly how you will respond to GLP-1 therapy or what your pregnancy risks will be. Rather, genetic predispositions in peptide pathways can help your provider assess whether GLP-1 continuation is metabolically critical for you during the preconception window, or whether alternative management strategies might be safer and equally effective. This precision approach supports more individualized family planning decisions.

If you are considering pregnancy or already pregnant, PlexusDx recommends consulting your obstetrician and endocrinologist before starting, stopping, or continuing GLP-1 medications. Our genetic test results, combined with your medical history and provider expertise, can support a more informed conversation about the timing of GLP-1 discontinuation, alternative therapies during pregnancy, and when to restart after delivery and lactation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

• Glp 1S
• Maximus Glp 1
• Found Glp 1
• Orderly Meds Glp 1